Radretumab

N/A

Report date: 2025/09/11 11:16:01

Base Information

Drug NameRadretumab
Drug Alias NameL19-I131L19-SIPI-L19-SIPI-131-L19-SIP131I-L19-SIP +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human +[7] 
Mechanisms of ActionAnti-FNAngiogenesis inhibitors
TargetsFibronectin
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBrain NeoplasmsHematologic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPhilogen Spa
China Registration ClassN/A

Develop Information

Active CompaniesPhilogen Spa
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsHodgkin Disease
Inactive IndicationsCarcinoma, Non-Small-Cell LungBrain NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia